Panacea Index Logo

Command Palette

Search for a command to run...

Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia.

Journal of intellectual disability research : JIDR
January 1, 1970
W Braam et al. (6 authors)
Journal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether melatonin treatment reduces daytime challenging behavior in individuals with intellectual disability (ID) and chronic insomnia by improving sleep parameters or circadian melatonin rhythmicity.

Results Summary

Melatonin treatment significantly reduced daytime challenging behavior (measured by SGZ scores), improved sleep latency, reduced night wakes, increased total sleep time, and advanced dim light melatonin onset (DLMO). However, changes in challenging behavior did not significantly correlate with changes in sleep parameters or DLMO.

Population

49 individuals (25 men, 24 women; mean age 18.2 years) with intellectual disability and chronic insomnia.

Effective Dosage

5 mg (2.5 mg for those under 6 years old) daily.

Duration

4 weeks.

Interactions

None mentioned.

Extracted Claims (7)
InterventionDirectionEndpointPopulationDosageImpactClaim #
melatonin
decrease
SGZ scores
persons with ID and chronic insomnia
-
significantly reduced
#1
melatonin
decrease
sleep latency
persons with ID and chronic insomnia
-
reduced
#2
melatonin
decrease
number of night wakes
persons with ID and chronic insomnia
-
reduced
#3
melatonin
decrease
duration of night wakes
persons with ID and chronic insomnia
-
reduced
#4
melatonin
increase
total sleep time
persons with ID and chronic insomnia
-
increased
#5
melatonin
increase
dim light melatonin onset (DLMO)
persons with ID and chronic insomnia
-
advanced
#6
melatonin
decrease
daytime challenging behaviour
persons with ID and chronic insomnia
-
decreases
#7
Abstract

BACKGROUND: Persons with intellectual disability (ID) and sleep problems exhibit more daytime challenging behaviours than persons with ID without sleep problems. Several anecdotal reports suggest that melatonin is not only effective in the treatment of insomnia, but also decreases daytime challenging behaviour. However, the effect of melatonin treatment on daytime challenging behaviour in persons with ID has not been investigated in a randomised controlled trial. METHOD: We investigated the effects of melatonin on challenging behaviour using data from two randomised controlled trials on the efficacy of melatonin on sleep problems in 49 persons (25 men, 24 women; mean age 18.2 years, SD = 17.1) with ID and chronic insomnia. Participants received either melatonin 5 mg (<6 years 2.5 mg) or placebo during 4 weeks. Daytime challenging behaviour was measured by the Storend Gedragsschaal voor Zwakzinnigen - Maladaptive Behaviour Scale for the Mentally Retarded (SGZ; Kraijer & Kema, 1994) at baseline week and the end of the fourth treatment week. Salivary dim light melatonin onset (DLMO) was measured at baseline and the last day of the fourth treatment week. Sleep logs were used to gather information on sleep parameters. RESULTS: Melatonin treatment significantly reduced SGZ scores, sleep latency, and number and duration of night wakes, and treatment increased total sleep time and advanced DLMO. However, after 4 weeks of treatment, change in SGZ scores did not significantly correlate with change in sleep parameters, nor with change in DLMO. Relatively strong correlations were found between change in SGZ scores, change in DLMO and number of night wakes. CONCLUSIONS: Melatonin treatment in persons with ID and chronic insomnia decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity.

Medical Subject Headings (MeSH)
AdolescentAdultChildChild, PreschoolChronic DiseaseCircadian RhythmFemaleHumansIntellectual DisabilityMaleMelatoninMiddle AgedRandomized Controlled Trials as TopicSleepSleep Initiation and Maintenance DisordersSocial Behavior DisordersWakefulness
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality80/10
Citation Metrics
Total Citations11
Citations/Year0.7
Relative Citation Ratio0.41
NIH Percentile21.9%
Research Impact Scores
APT Score0.25
Weight Score1.67
Normalized Score0.70
Related Supplements
Melatonin decreases daytime challenging behaviour in persons... | Panacea Index